Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Increases By 118.3%

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 51,300 shares, a growth of 118.3% from the March 15th total of 23,500 shares. Based on an average daily volume of 150,200 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.7% of the shares of the stock are sold short.

Revelation Biosciences Trading Down 12.4 %

REVB stock opened at $3.05 on Wednesday. Revelation Biosciences has a 1-year low of $2.36 and a 1-year high of $60.80. The stock has a market cap of $2.76 million, a price-to-earnings ratio of -0.01 and a beta of 0.23. The company’s 50 day moving average is $3.41 and its 200 day moving average is $7.55.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.